SBIR/STTR Research Award
Novel bioengineering platform to produce natural RNAi agents
Award amount
$224,158Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AIMRNA INC
- Proposal award date
- 2018-08-03
- Contract end date
- 2019-07-31
- UEI
- XGCNK4KJKYH3
- Solicitation number
- PA17-302
- Topic code
- 400
Research abstract
PROJECT SUMMARY
Noncoding RNAsncRNAshave revolutionized biomedical research as master regulators of all known
biological processes through the modulation of target gene expressionFurthermorencRNAs are
attractive candidates for the treatment of human diseasesHowevercurrent ncRNA research and
development is limited to the use of chemically engineered orsynthesized ncRNA agentse gmiRNAs and siRNAsthat are decorated with various and extensive artificial modificationsThis is in
accordance with the termination of a number of siRNA miRNA oligonucleotide drugs from further clinical
investigationsdue to the induction of adverse immune responses in patientsAlthough the exact causes
of immunogenicity remain undisclosedartificial modifications have been well documented to provoke
immunogenicity as recognized by toll like receptorsThereforewe have made large efforts to develop
novel bioengineering techniques for the production of natural ncRNA agentsOur efforts have led to
the identification of stable tRNA pre miRNA hybrid carriers for large scale expression of recombinant
miRNAs and siRNAs in a common strain of EcoliOur studies have demonstrated that bioengineered
miRNA siRNA agentsBERAscarry no or just a few natural posttranscriptionally modified nucleosides
and exhibit favorable stability within human cellsFurthermoreBERAs are biologically active in
modulating target gene expression and cancer cellular processese gcell proliferation and
chemosensitivityetcin vitroand suppress tumor progression in animal models in vivoGiven these
exciting preliminary findingswe hypothesize that the tRNA pre miRNA based technology may be refined
and standardized to achieve a more consistenthigher yield production of fully humanized natural RNAi
agentsTo test this hypothesiswe will optimize pre miRNA to improve expression yieldandgtof total
RNAsand incorporate human tRNAs to offer fully humanized ncRNA carriersAimIn additionwe will
develop a standardized pipeline to produce a collectionof ready to use BERAsand critically
compare the efficacy and safety of model BERAs with synthetic miRNA mimicsAimThis project will
establish a novel ncRNA bioengineering platform toward high yield production of fully humanized RNAi
agents and offer BERAs as a new class of natural ncRNA agents for research and development PROJECT NARRATIVE
The proposed research is to establish a novel ncRNA bioengineering platform to achieve a consistenthigher yield production of natural and fully humanized ncRNA moleculesand to employ this technology to
produce a panel of ready to use biologic miRNA siRNA agentsThis technology is distinguished from
existing technologies pursued by all other companies that produce and study chemicallyengineered synthetized miRNA siRNA molecules bearing various and extensive artificial modificationsResults from this project are anticipated to open a new avenue for the production of natural ncRNA agents
for research and development
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Platform for Optimizing Yield and Quality of Therapeutic AAV Vector Manufacturing via Synthetic Helper Genes
- Ultra-low-temperature (6 K) static NMR-DNP for metalloproteins, proteins in cells, and materials
- Dynamical Diffraction Analysis for 3D Electron Crystallography
- Synthetic biology approaches for bio-orthogonal labeling of circular RNAs
- Break Wave lithotripsy to fragment large kidney stones